Skip to main content
PMC home page
CNS Drug Reviews logoLink to CNS Drug Reviews
. 2006 Jun 7;9(4):343–358. doi: 10.1111/j.1527-3458.2003.tb00259.x

BAY 38–7271: A Novel Highly Selective and Highly Potent Cannabinoid Receptor Agonist for the Treatment of Traumatic Brain Injury

Frank Mauler 1,✉, Ervin Horváth 1, Jean De Vry 1, Rainer Jäger 2, Thomas Schwarz 3, Steffen Sandmann 3, Corinna Weinz 4, Roland Heinig 5, Michael Böttcher 5
PMCID: PMC6741701  PMID: 14647528

ABSTRACT

Traumatic brain injury (TBI) is the most common cause of mortality and morbidity in adults under 40 years of age in industrialized countries. Worldwide the incidence is increasing, about 9.5 million people are hospitalized per year due to TBI, and the death rate is estimated to be more than one million people per year. Recently BAY 38–7271 has been characterized as a structurally novel, selective and highly potent cannabinoid CB1/CB2 receptor agonist in vitro and in vivo with pronounced neuroprotective efficacy in a rat traumatic brain injury model, showing a therapeutic window of at least 5 h. Furthermore, neuroprotective efficacy was also found in models of transient and permanent occlusion of the middle cerebral artery and brain edema models as well. In this article we review the in vitro and in vivo pharmacology of BAY 38–7271, the results from acute and subacute toxicity studies, pharmacokinetics and drug metabolism in animals and healthy male volunteers. In phase I studies BAY 38–7271 was safe and well tolerated when administered by i.v. infusion for either 1 or 24 h.

As the doses of BAY 38–7271 in animals needed for maximal neuroprotective efficacy were significantly lower than those inducing typical cannabinoid‐like side effects, it is to be expected that the compound will offer a novel therapeutic approach with a favorable therapeutic window for the treatment of TBI or cerebral ischemia.

Keywords: BAY 38–7271, Cannabinoid agonists, Cannabinoid receptors, Neuroprotection, Traumatic brain injury

Full Text

The Full Text of this article is available as a PDF (151.7 KB).

References

  • 1. Abood ME, Rizvi G, Sallapudi N, McAllister SD. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neurosci Lett 2001;309:197–201. [DOI] [PubMed] [Google Scholar]
  • 2. Aceto MD, Scates SM, Lowe JA, Martin BR. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A. Eur J Pharmacol 1995;282:R1–R2. [DOI] [PubMed] [Google Scholar]
  • 3. Aceto MD, Scates SM, Lowe JA, Martin BR. Dependence on δ9‐tetrahydrocannabinol: Studies on precipitated and abrupt withdrawal. J Pharmacol Exp Ther 1996;278:1290–1295. [PubMed] [Google Scholar]
  • 4. Balster RL, Prescott WR. Δ9‐Tetrahydrocannabinol discrimination in rats as a model for cannabis intoxication. Neurosci Biobehav Rev 1992;16:55–62. [DOI] [PubMed] [Google Scholar]
  • 5. Barrett RL, Wiley JL, Balster RL, Martin BR. Pharmacological specificity of Δ9‐tetrahydrocannabinol discrimination in rats. Psychopharmacology 1995;118:419–424. [DOI] [PubMed] [Google Scholar]
  • 6. Barth F. Cannabinoid receptor agonists and antagonists. Expert Opin Ther Patents 1998;8:301–313. [Google Scholar]
  • 7. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: Evaluation of the model and development of a neurologic examination. Stroke 1986;17:472–476. [DOI] [PubMed] [Google Scholar]
  • 8. Biegon A, Joseph AB. Development of HU‐211 as a neuroprotectant for ischemic brain damage. Neurol Res 1995;17:275–280. [DOI] [PubMed] [Google Scholar]
  • 9. Belayev L, Busto R, Zhao W, Ginsberg MD. HU‐211, a novel noncompetitive N‐methyl‐D‐aspartate antagonist, improves neurological deficit and reduces infarct volume after reversible focal cerebral ischemia in the rat. Stroke 1995;26:2313–2319. [DOI] [PubMed] [Google Scholar]
  • 10. Boxer PA, Bigge CF. Mechanisms of neuronal cell injury/death and targets for drug intervention. Drug Discovery Today 1997;2:219–228. [Google Scholar]
  • 11. Carlisle SJ, Marciano‐Cabral F, Staab A, Ludwick C, Cabral GA. Differential expression of the CB2 cannabinoid receptor by rodent macrophages and macrophage‐like cells in relation to cell activation. Int Immunopharmacol 2002;2:69–82. [DOI] [PubMed] [Google Scholar]
  • 12. De Keyser J, Sulter G, Luiten PG. Clinical trials with neuroprotective drugs in acute ischaemic stroke: Are we doing the right thing TINS 1999;22:535–540. [DOI] [PubMed] [Google Scholar]
  • 13. De Vry J, Dietrich H, Glaser T, Heine HG et al. BAY × 3702. Drugs Future 1997;22:341–349. [Google Scholar]
  • 14. De Vry J. Behavioral pharmacology of cannabinoids in animals. Eur Neuropsychopharmacol 2002;12:S129. [Google Scholar]
  • 15. De Vry J, Jentzsch KR. Discriminative stimulus effects of BAY 38–7271, a novel cannabinoid receptor agonist. Eur J Pharmacol 2002;457:147–152. [DOI] [PubMed] [Google Scholar]
  • 16. De Vry J, Jentzsch KR. Intrinsic activity estimation of cannabinoid CB1 receptor ligands in a drug discrimination paradigm. Behav Pharmacol 2003:14:471–476. [DOI] [PubMed] [Google Scholar]
  • 17. Dirnagl U, Iadecola C, Moskowitz MA. Pathobiology of ischaemic stroke: An integrated view. TINS 1999;22:391–397. [DOI] [PubMed] [Google Scholar]
  • 18. Gaoini Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc 1964;86:1646–1647. [Google Scholar]
  • 19. Gerdeman G, Lovinger DM. CB1 cannabinoid receptor inhibits synaptic release of glutamate in rat dorsolateral striatum. J Neurophysiol 2001;85:468–471. [DOI] [PubMed] [Google Scholar]
  • 20. Gifford AN, Bruneus M, Gatley SJ, Lan R, Makriyannis A, Volkow ND. Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther 1999;288:478–483. [PubMed] [Google Scholar]
  • 21. Grundy RI, Rabuffetti M, Beltramo M. Cannabinoids and neuroprotection. Mol Neurobiol 2001;24:29–51. [DOI] [PubMed] [Google Scholar]
  • 22. Giulian D, Baker TJ, Shih LC, Lachman LB. Interleukin 1 of the central nervous system is produced by ameboid microglia. J Exp Med 1986;164:594–604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Hansen HH, Schmid PC, Bittigau P et al. Anandamide, but not 2‐arachidonoylglycerol, accumulates during in vivo neurodegeneration. J Neurochem 2001;78:1415–1427. [DOI] [PubMed] [Google Scholar]
  • 24. Hampson AJ, Grimaldi M, Axelrod J, Wink D. Cannabidiol and (‐)Δ9‐tetrahydrocannabinol are neuroprotective antioxidants. Proc Natl Acad Sci USA 1998;95:8268–8273. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Hampson AJ, Grimaldi M, Lolic M, Wink D, Rosenthal R, Axelrod J. Neuroprotective antioxidants from marijuana. Ann New York Soc Sci 2000;99:274–282. [PubMed] [Google Scholar]
  • 26. Kalsbeek WD, McLaurin RL, Harris BS, Miller JD. The national head and spinal cord injury survey: Major findings. J Neurosurg 1980;58:S19–S31. [PubMed] [Google Scholar]
  • 27. Kim DJ, Thayer SA. Activation of CB1 cannabinoid receptors inhibits neurotransmitter release from identified synaptic sites in rat hippocampal cultures. Brain Res 2000;852:398–405. [DOI] [PubMed] [Google Scholar]
  • 28. Knoblach SM, Fan L, Faden AI. Early neuronal expression of tumor necrosis factor‐alpha after experimental brain injury contributes to neurological impairment. J Neuroimmunol 1999;95:115–125. [DOI] [PubMed] [Google Scholar]
  • 29. Kornhuber J, Weller M. Psychotogenicity and N‐methyl‐D‐aspartate receptor antagonism: Implications for neuroprotective pharmacotherapy. Biol Psychiatry 1997;41:135–144. [DOI] [PubMed] [Google Scholar]
  • 30. Lees KR. Cerestat and other NMDA antagonists in ischemic stroke. Neurology 1997;49:S66–S69. [DOI] [PubMed] [Google Scholar]
  • 31. Leker RR, Gai N, Mechoulam R, Ovadia H. Drug‐induced hypothermia reduces ischemic damage: Effects of the cannabinoid HU‐210. Stroke 2003;34:2000–2006. [DOI] [PubMed] [Google Scholar]
  • 32. Leker RR, Shohami E, Abramsky O, Ovadia H. Dexanabinol; a novel neuroprotective drug in experimental focal cerebral ischemia. J Neurol Sci 1999;162:114–119. [DOI] [PubMed] [Google Scholar]
  • 33. Leong SK, Ling EA. Amoeboid and ramified microglia: Their interrelationship and response to brain injury. Glia 1992;6:39–47. [DOI] [PubMed] [Google Scholar]
  • 34. Lipton P. Ischemic cell death in brain neurons. Physiol Rev 1999;79:1431–1568. [DOI] [PubMed] [Google Scholar]
  • 35. Maas IR. Neuroprotective agents in traumatic brain injury. Exp Opin Invest Drugs 2001;10:753–767. [DOI] [PubMed] [Google Scholar]
  • 36. Martin BR, Compton DR, Thomas BF, et al. Behavioral, biochemical, and molecular modeling evaluations of cannabinoid analogs. Pharmacol Biochem Behav 1991;40:471–478. [DOI] [PubMed] [Google Scholar]
  • 37. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561–564. [DOI] [PubMed] [Google Scholar]
  • 38. Mauler F, Fahrig T, Horváth E, Jork R. Inhibition of evoked glutamate release by the neuroprotective 5‐HT1A receptor agonist BAY × 3702 in vitro and in vivo. Brain Res 2001;888:150–157. [DOI] [PubMed] [Google Scholar]
  • 39. Mauler F, Hinz V, Augstein K‐H, Faßbender M, Horváth E. Neuroprotective and brain edema reducing efficacy of the novel cannabinoid receptor agonist BAY 38–7271. Brain Res 2003;989:99–111. [DOI] [PubMed] [Google Scholar]
  • 40. Mauler F, Mittendorf J, Horváth E, De Vry J. Characterization of the diarylether sulfonylester (‐)‐(R)‐3‐(2‐hydroxymethylindanyl‐4‐oxy)phenyl‐4,4,4‐trifluoro‐1‐sulfonate (BAY 38–7271) as a potent cannabinoid receptor agonist with neuroprotective properties. J Pharmacol Exp Ther 2002;302:359–368. [DOI] [PubMed] [Google Scholar]
  • 41. Miller JD, Bullock R, Graham DI, Chen MH, Teasdale GM. Ischemic brain damage in a model of acute subdural hematoma. Neurosurgery 1990;27:433–439. [DOI] [PubMed] [Google Scholar]
  • 42. Molina‐Holgado F, Molina‐Holgado E, Guaza C, Rothwell NJ. Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide‐induced nitric oxide release in astrocyte cultures. J Neurosci Res 2002;67:829–836. [DOI] [PubMed] [Google Scholar]
  • 43. Mu J, Zhuang SY, Kirby MT, Hampson RE, Deadwyler SA. Cannabinoid receptors differentially modulate potassium A and D currents in hippocampal neurons in culture. J Pharmacol Exp Ther 1999;291:893–902. [PubMed] [Google Scholar]
  • 44. Munro S, Thomas KL, Abu‐Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993;365:61–65. [DOI] [PubMed] [Google Scholar]
  • 45. Nagasawa H, Kogure K. Correlation between cerebral blood flow and histologic changes in a new rat model of middle cerebral artery occlusion. Stroke 1989;20:1037–1043. [DOI] [PubMed] [Google Scholar]
  • 46. Nagayama T, Sinor AD, Simon RP, et al. Cannabinoids and neuroprotection in global and focal cerebral ischemia and in neuronal cultures. J Neurosci 1999;19:2987–2995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Olney JW, Labruyere J, Pirce MT. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 1989;244:1360–1362. [DOI] [PubMed] [Google Scholar]
  • 48. Panikashvili D, Simeonidou C, Ben‐Shabat S, et al. An endogenous cannabinoid (2‐AG) is neuroprotective after brain injury. Nature 2001;413:527–531. [DOI] [PubMed] [Google Scholar]
  • 49. Pério A, Rinaldi‐Carmona M, Maruani J, Barth F, Le Fur G, Soubrié P. Central mediation of the cannabinoid cue: Activity of a selective CB1 antagonist, SR 141716A. Behav Pharmacol 1996;7:65–71. [PubMed] [Google Scholar]
  • 50. Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther 1997;74:129–180. [DOI] [PubMed] [Google Scholar]
  • 51. Pertwee RG. Effects of cannabinoids on thermoregulation: A brief review In: Harvey DJ, Paton W, Nahas GG, Eds. Marihuana '84. Proceedings of the Oxford Symposium on Cannabis. Oxford : IRL Press Limited, 1984:263–277. [Google Scholar]
  • 52. Rinaldi‐Carmona M, Barth F, Héaulme M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett 1994;350:240–244. [DOI] [PubMed] [Google Scholar]
  • 53. Sawada M, Kondo N, Suzumura A, Marunouchi T. Production of tumor necrosis factor‐alpha by microglia and astrocytes in culture. Brain Res 1989;491:394–397. [DOI] [PubMed] [Google Scholar]
  • 54. Shimizu‐Sasamata M, Bosque‐Hamilton P, Huang PL, Moskowitz MA, Lo EH. Attenuated neurotransmitter release and spreading depression‐like depolarizations after focal ischemia in mutant mice with disrupted type I nitric oxide synthase gene. J Neurosci 1998;18:9564–9571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 55. Shen M, Thayer SA. Cannabinoid receptor agonists protect cultured rat hippocampal neurons from excitotoxicity. Mol Pharmacol 1998;54:459–462. [DOI] [PubMed] [Google Scholar]
  • 56. Striem S, Bar‐Joseph A, Berkovitch Y, Biegon A. Interaction of dexanabinol (HU‐211), a novel NMDA receptor antagonist, with the dopaminergic system. Eur J Pharmacol 1997;338:205–213. [DOI] [PubMed] [Google Scholar]
  • 57. Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F. Increase in IL‐6, IL‐1 and TNF levels in rat brain following traumatic lesion. Influence of pre‐ and post‐traumatic treatment with Ro5–4864, a peripheral‐type (p site) benzodiazepine ligand. J Neuroimmunol 1993;42:177–185. [DOI] [PubMed] [Google Scholar]
  • 58. Tsou K, Patrick SL, Walker JM. Physical withdrawal in rats tolerant to δ9‐tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist. Eur J Pharmacol 1995;280:R13–R15. [DOI] [PubMed] [Google Scholar]
  • 59. van der Stelt M, Hansen HH, Veldhuis WB, et al. Biosynthesis of endocannabinoids and their modes of action in neurodegenerative diseases. Neurotox Res 2003;5:183–200. [DOI] [PubMed] [Google Scholar]
  • 60. Waksman Y, Olson JM, Carlisle SJ, Cabral GA. The central cannabinoid receptor (CB1) mediates inhibition of nitric oxide production by rat microglial cells. J Pharmacol Exp Ther 1999;288:1357–1366. [PubMed] [Google Scholar]
  • 61. Walter L, Franklin A, Witting A, et al. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003;23:1398–1405. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62. Warlow CP. Epidemiology of stroke. Lancet 1998;352:SIII, 1–4. [DOI] [PubMed] [Google Scholar]
  • 63. Wiley JL, Barrett RL, Lowe J, Balster RL, Martin BR. Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology 1995;34:669–676. [DOI] [PubMed] [Google Scholar]
  • 64. Wiley JL, Lowe JA, Balster RL, Martin BR. Antagonism of the discriminative stimulus effects of δ9‐tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 1995;275:1–6. [PubMed] [Google Scholar]
  • 65. Woodroofe MN, Sarna GS, Wadhwa M, et al. Detection of interleukin‐1 and interleukin‐6 in adult rat brain, following mechanical injury, by in vivo microdialysis: Evidence of a role for microglia in cytokine production. J Neuroimmunol 1991;33:227–236. [DOI] [PubMed] [Google Scholar]
  • 66. Yenari MA, Bell TE, Kotake AN, Powell M, Steinberg GK. Dose escalation safety and tolerance study of the competitive NMDA antagonist selfotel (CGS 19755) in neurosurgery patients. Clin Neuropharmacol 1998;21:28–34. [PubMed] [Google Scholar]
  • 67. Zhao Q, Smith ML, Siesjö BK. The omega‐conopeptide SNX‐111, an N‐type calcium channel blocker, dramatically ameliorates brain damage due to transient focal ischaemia. Acta Physiol Scand 1994;150:459–461. [DOI] [PubMed] [Google Scholar]

Articles from CNS Drug Reviews are provided here courtesy of Wiley

RESOURCES